Navigation Links
Low vitamin D during pregnancy linked to pre-eclampsia
Date:9/7/2007

PITTSBURGH, Sept. 7 Vitamin D deficiency early in pregnancy is associated with a five-fold increased risk of preeclampsia, according to a study from the University of Pittsburgh Schools of the Health Sciences reported this week in the Journal of Clinical Endocrinology and Metabolism.

A serious complication of pregnancy marked by soaring blood pressure and swelling of the hands and feet, preeclampsia is the leading cause of premature delivery and maternal and fetal illness and death worldwide, conservatively projected to contribute to 76,000 deaths each year. Preeclampsia, also known as toxemia, affects up to 7 percent of first pregnancies, and health care costs associated with preeclampsia are estimated at $7 billion a year in the United States alone, according to the Preeclampsia Foundation.

Our results showed that maternal vitamin D deficiency early in pregnancy is a strong, independent risk factor for preeclampsia, said Lisa M. Bodnar, Ph.D., M.P.H., R.D., assistant professor of epidemiology at the University of Pittsburgh Graduate School of Public Health (GSPH) and lead author of the study. Women who developed preeclampsia had vitamin D concentrations that were significantly lower early in pregnancy compared to women whose pregnancies were normal. And even though vitamin D deficiency was common in both groups, the deficiency was more prevalent among those who went on to develop preeclampsia.

For this investigation, Dr. Bodnar and her colleagues evaluated data and banked blood samples taken from women and newborns between 1997 and 2001 at Magee-Womens Hospital of the University of Pittsburgh Medical Center (UPMC) and affiliated private obstetrician practices. Data were analyzed for 1,198 women enrolled in the Pregnancy Exposures and Preeclampsia Prevention Study, a prospective survey designed to examine factors that may predispose women to preeclampsia. Out of this group, 55 cases of preeclampsia and 220 controls were selected f
'/>"/>

Contact: Michele D. Baum
BaumMD@upmc.edu
412-647-3555
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. Does vitamin C help prevent or treat the common cold? Maybe not, after all.
2. Vitamin As paradoxical role in influencing symmetry during embryonic development revealed
3. OHSU research shows vitamin C counteracts some negative impacts of smoking on unborn babies
4. Vitamin D deficiency widespread during pregnancy
5. Natural vitamin E tocotrienol reaches blood at protective levels
6. Poor athletic performance linked to vitamin deficiency
7. MIT biologists solve vitamin puzzle
8. Cocoa vitamin health benefits could outshine penicillin
9. Misusing vitamin to foil drug test may be toxic; plus, it doesnt work
10. Vitamins: Science doesnt always match policy
11. Fat overrides effects of vitamin C

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... from around the world will gather in Boston Nov. ...ets and Cancer Therapeutics International Conferen...on important cancer therapies in development. , ...ctively we need a greater understanding of the act...id Lewis Cantley, Ph.D., director of the cancer ce...
(Date:11/8/2009)...ne through deletion of genetic material on chromos...s in learning and behavior, said a consortium of r....bcm.edu ) in a report that appears online today i...h goes about 95 percent of the way to pinning thes...his gene," said Dr. Arthur L. Beaudet ( http://www...
(Date:11/6/2009)... of the publication of On the Origin of Species, t...) is publishing open access two peer-reviewed arti...s into evolution. , The two articles are by Kevin... and James T. Costa of Western Carolina University...n," appeared in the October issue of the AIBS jour...
Breaking Biology News(10 mins):Developmental delay could stem from nicotinic receptor deletion 2Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine 4938 1Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine 4938 2Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine 4938 3Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine 4938 4Martek Announces Third Quarter 2009 Financial Results 56082 1Martek Announces Third Quarter 2009 Financial Results 56082 2Martek Announces Third Quarter 2009 Financial Results 56082 3Martek Announces Third Quarter 2009 Financial Results 56082 4Martek Announces Third Quarter 2009 Financial Results 56082 5Martek Announces Third Quarter 2009 Financial Results 56082 6Martek Announces Third Quarter 2009 Financial Results 56082 7Martek Announces Third Quarter 2009 Financial Results 56082 8Martek Announces Third Quarter 2009 Financial Results 56082 9Martek Announces Third Quarter 2009 Financial Results 56082 10Martek Announces Third Quarter 2009 Financial Results 56082 11Martek Announces Third Quarter 2009 Financial Results 56082 12Gentiva 28R 29 Health Services Completes Acquisition of Home Health Agency 56080 1Gentiva 28R 29 Health Services Completes Acquisition of Home Health Agency 56080 2Gentiva 28R 29 Health Services Completes Acquisition of Home Health Agency 56080 3
...he length of nectar spurs--the long tubes leading ...owers to match the tongue lengths of the pollinato... , The researchers were Justen Whittall of the Uni... the University of California at Santa Barbara. Th...(NSF). Their results appear in this week,s issue o...
...ergy and Infectious Diseases (NIAID), a component ...red a survival mechanism in a common type of bacte... bacteria protect itself by warding off attacks fr...e molecules sent by the body to kill bacteria. , B...and gram-negative, with the primary difference bei...
...tations, but just how these mutations contribute t...ew clue comes from scientists at the University of... and Public Health. Their research indicates that ...d, may specifically increase the risk of melanomas...n the NRAS gene, was found in patients who had sun...
Other Biology News:Columbine flowers develop long nectar spurs in response to pollinators 2Newly found sensing system enables certain bacteria to resist human immune defenses 2Sun exposure early in life linked to specific skin cancer gene mutation 2
(Date:11/6/2009)...Austria, November 6 EUCODIS Biosci...ring, and marketing enzymes for the,chemical indus...earch,agreement with Bio Sidus, the leading biopha...he agreement gives EUCODIS Bioscience exclusive ac...Bio Sidus, proprietary collection of,psychrophilic...
(Date:11/6/2009)...if., Nov. 6 Intarcia Therapeutics,...A 650 (DUROS® continuous delivery of exenatid... the Ninth Annual Diabetes Technology Meeting in S....com/cgi-bin/prnh/20050301/SFTU126LOGO ) ,, C...TCA 650 Lowers Plasma Glucose, HbA1c and Reduces W...
(Date:11/5/2009)...Colo., Nov. 5 The endangered black...estern U.S. This rare carnivore feeds on prairie ...lague and often entire population die-offs in town...S) has implemented a ferret breeding program and h...eir formerly native habitat. Unfortunately, plagu...
(Date:11/5/2009)...all on Thursday, November 5, 2009 at 4:30 p.m. Eas.../PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals...XI ) today reported unaudited financial results fo...r 30, 2009 and reviewed the Company,s highlights f...consolidated results reflect the operations of Onc...
Breaking Biology Technology:EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8
... two-thirds (67%) of Americans are generally conce...pply, according to a 2008 National Consumer Water ...adlines warning of contaminants1 (i.e. lead, radiu... stirred controversy and confusion. Consumers are ...le plastic bottles isn’t an environmentally-...
...ex, Inc. ("ChromaDex"),today announced that effect...I Acquisition, Inc. ("CDI"), the wholly-owned subs...tin Board: CDYE). The transaction,enables ChromaDe... publicly,traded, which will help it be better pos...wing marketplace. The business and operations of C...
...ction Agency Contract Will Support Development o...ial Broad-Spectrum Anti-Viral Ag...euticals, Inc. (Nasdaq: PPHM ), a clinical stage ...tibodies for the treatment of cancer and,hepatitis...ntered into a,five-year contract worth up to $44.4...
Other Biology Technology: Culligan's New Aqua-Cleer Advanced Drinking Water SystemProvides Clean, Quality Water Customized for Every Home 2 Culligan's New Aqua-Cleer Advanced Drinking Water SystemProvides Clean, Quality Water Customized for Every Home 3ChromaDex, Inc. Announces Completion of Reverse Merger With Cody Resources, Inc. 2Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers 2Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers 3Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers 4Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers 5
Rabbit Anti-Mouse Junctophilin-4, C-Terminus Monoclonal Antibody, Unconjugated, Clone PADZMD.487 from Invitrogen
...PCR Cloning Kits are designed to speed up the PCR ...s, regardless of sequence or type of polymerase us...ding those that are difficult to clone by other PC...for potentially detrimental proteins can be cloned...
Mounting Medium from BioVision
GeneAmp High Fidelity PCR from Applied Biosystems
Biology Products: